Clinical Trials
17 trialsNCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05734495 2026-05-28
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03322865 2026-05-06
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Phase 2 Active not recruiting
NCT03474744 2026-05-06
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
University of Ulm
Phase 2 Active not recruiting
NCT03697512 2026-04-08
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT04646395 2026-04-06
Study of Acalabrutinib and Tafasitamab in MZL Patients
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT07480863 2026-04-02
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT05783596 2026-03-16
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT06583837 2026-02-27
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Phase 2 Active not recruiting
NCT01808599 2026-01-15
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT03674411 2026-01-06
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT07247383 2025-11-25
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT03888105 2025-10-15
ELM-2
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT04416451 2025-07-02
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting